Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fetomaternal alloimmune thrombocytopenia.

R Ahya1, M L Turner, S J Urbaniak

  • 1Academic Transfusion Medicine Unit, Department of Medicine and Therapeutics, University of Aberdeen, UK. r.ahya@abdn.ac.uk

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|January 5, 2002
PubMed
Summary

Neonatal thrombocytopenia, often caused by fetomaternal platelet incompatibility, can be diagnosed using advanced molecular techniques. Early identification and management, including antigen-negative platelet transfusions, are crucial for preventing intracranial bleeding in newborns.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing electron affinity and tuning band gap in donor-acceptor organic semiconductors by benzothiadiazole directed C-H borylation.

Chemical science·2017
Same author

Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells.

New biotechnology·2014
Same author

Use of IL3 and chromatin-modifying reagents valproic acid and 5-aza-2'-deoxycytidine to affect mobilized peripheral blood CD34+ cell fate decisions.

Vox sanguinis·2014
Same author

Quantal and graded stimulation of B lymphocytes as alternative strategies for regulating adaptive immune responses.

Nature communications·2013
Same author

UK approach to assessing assays and filters designed to reduce the risk of transfusion-transmitted vCJD.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2013
Same author

Drug modification of LPS-stimulated human monocyte-derived dendritic cells.

British journal of biomedical science·2012

Area of Science:

  • Neonatal Hematology
  • Immunogenetics
  • Molecular Diagnostics

Background:

  • Neonatal thrombocytopenia is a common hematological issue, affecting 1-4% of newborns and up to 40% in intensive care.
  • Fetomaternal platelet incompatibility is the leading cause of severe neonatal thrombocytopenia.
  • Advances in molecular techniques have improved diagnosis and fetal status determination.

Purpose of the Study:

  • To investigate the role of human platelet antigens (HPAs) in neonatal thrombocytopenia.
  • To explore the association between maternal HLA class II DRB3*0101 and HPA-1a alloimmunization.
  • To evaluate the effectiveness of antenatal screening for HPA-1b homozygosity and antibody titres.

Main Methods:

  • Genotyping of fetuses, neonates, and parents using polymerase chain reaction-sequence specific primers (PCR-SSP).

Related Experiment Videos

  • Simultaneous genotyping for HPA-1, 2, 3, and 5.
  • Monitoring antibody titres during pregnancy and correlating with HLA-DRB3*0101.

    • Main Results:

    • Human platelet antigen (HPA)-1a is the most common cause in Caucasians (90%), followed by HPA-5b and HPA-3a.
    • Maternal HLA class II DRB3*0101 is strongly associated with HPA-1a alloimmunization.
    • A significant association exists between severe thrombocytopenia and third-trimester anti-HPA titres >1:32.
    • Routine antenatal screening in Scotland identified 1.9% of women as HPA-1b homozygous, with 9% antibody positivity.

    Conclusions:

    • Molecular genotyping facilitates accurate diagnosis of fetomaternal HPA incompatibility.
    • Antenatal screening for HPA-1b homozygosity can identify at-risk pregnancies.
    • Further studies are needed to establish routine antenatal screening protocols for FMAIT.